Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Vistagen reported a net loss primarily driven by research and development expenses for its CNS pipeline, including Phase 3 trials for fasedienol. The company maintains a cash runway to support operations through upcoming clinical milestones, though it currently generates no product revenue.
Lifeloc Technologies reported a net loss of $84,931 for the third quarter of 2026, an improvement from the $263,439 loss in the prior year period, driven by a 12% increase in total revenues. For the nine months ended September 30, 2026, the company reduced its operating loss to $281,649 compared to $893,139 in 2025, while securing a $500,000 related-party term loan to bolster cash reserves.
Hennessy Capital Investment Corp. VIII reported net income of $4.09 million for the nine months ended September 30, 2026, primarily driven by $5.41 million in interest earned on cash held in the Trust Account. As a blank check company, it has not yet commenced operations or selected a business combination target, and it maintains a shareholders' deficit of $4.96 million due to the accretion of Class A ordinary shares to redemption value.
AEVEX Corp. reported Q3 2026 revenue of $189.7 million, a 56.5% increase year-over-year, driven by growth in its Airborne Systems segment and the acquisition of BlackSea Technologies. The company raised its full-year 2026 revenue guidance to a range of $820-$840 million and Adjusted EBITDA guidance to $128-$132 million. Despite revenue growth, the company reported a net loss of $16.8 million primarily due to a significant increase in income tax provisions.
Term
Q3 2026
“AEVEX delivered strong third-quarter results with total revenue and Adjusted EBITDA growth, and related margin expansion. Beyond the success in our legacy business, we announced and closed on our first acquisition as a public company, with the purchase of BlackSea Technologies. This combination expands our capabilities across air, surface and subsea domains, strengthens our production infrastructure and is creating new opportunities to deliver collaborative, mission-focused solutions to a broader set of customers.”
Roger Wells, Chief Executive Officer of AEVEX
“The strength of our third quarter performance, end market demand and the addition of BlackSea gives us the confidence to raise our full-year outlook. We look forward to continuing to advance the strategic priorities we outlined at the IPO earlier this year, as we are scaling production, broadening our mission and customer reach, investing ahead of the threat and building a differentiated multi-domain autonomous systems company.”
American Drive Acquisition Company reported a net income of $4,267,562 for the nine months ended September 30, 2026, primarily driven by $6,221,191 in interest earned on marketable securities held in the Trust Account. The company remains a shell company with $236,450,412 in its Trust Account and 23,000,000 Class A ordinary shares subject to possible redemption.
Ashford Hospitality Trust reported a net income of $14.2 million for the quarter ended September 30, 2026, a significant improvement from a $62.7 million loss in the prior year period, primarily driven by a $59.3 million gain on the disposition of assets. Total hotel revenue decreased to $214.3 million from $265.7 million year-over-year, reflecting a smaller portfolio as the company continues to divest properties and address debt.
Laird Superfood reported a significant increase in net sales to $41.95 million for the third quarter of 2026, compared to $12.90 million in the prior year period. The company achieved a net income of $1.73 million for the quarter, a substantial improvement from a net loss of $975,066 in Q3 2025, driven by higher gross profits and a change in the fair value of contingent consideration.
MDB Capital Holdings reported a net loss of $32.5 million for the nine months ended September 30, 2026, compared to a $19.5 million loss in the prior year, driven largely by a $13.2 million loss from an equity method investee and significant unrealized losses on investment securities. Total assets decreased from $63.7 million at year-end 2025 to $37.5 million, primarily due to the impairment and losses associated with their equity method investment.
Inhibrx Biosciences reported a net loss of $108.8 million for the nine months ended September 30, 2026, compared to $107.2 million in the prior year. The company significantly increased its cash position to $199.5 million following $175.0 million in debt proceeds, while its accumulated deficit grew to $355.0 million.
For the nine months ended September 30, 2026, Sculptor Diversified Real Estate Income Trust reported total revenues of $46.7 million and net income of $20.1 million, a significant improvement from the $1.6 million net loss in the prior year period. The company's total assets grew to $1.06 billion, driven by increased investments in real estate debt and unconsolidated entities.
Investcorp Credit Management BDC reported financial results for its fiscal quarter ended September 30, 2026, showing a net investment loss of $1.8 million ($0.13 per share). Net asset value (NAV) decreased to $3.02 per share from $3.44 in the prior quarter, driven by $3.0 million in net unrealized losses. Management waived all management and incentive fees for the period to support the company's financial position.
Term
Q1 2027
“Our focus this quarter was to maintain asset quality as we evaluated strategic alternatives to enhance shareholder value”
Suhail A. Shaikh, chief executive officer of ICMB
“Liquidity remained a high priority for us during the quarter.”
Kennedy Lewis Capital Company reported total investment income of $94.3 million and net investment income of $52.1 million for the nine months ended September 30, 2026. Total assets grew to $1.38 billion, driven by an increase in the fair value of the investment portfolio, while net asset value per share for Class I shares decreased slightly from $20.04 to $19.74 during the period.
Finward Bancorp reported net income of $5.7 million for the first nine months of 2026, a slight decrease from $6.1 million in the prior year period. Total assets decreased slightly to $2.01 billion as of September 30, 2026, while stockholders' equity was significantly impacted by a $21.9 million unrealized loss on securities available-for-sale.
For the nine months ended September 30, 2026, Mobility reported net sales of $2,480 million, a slight increase from $2,422 million in the prior year, while net income rose to $140 million from $123 million. The company is currently preparing for a Reverse Morris Trust transaction to combine with Dana Incorporated, which is expected to close in the first four months of 2027.
Bain Capital GSS Investment Corp. reported net income of $12.17 million for the nine months ended September 30, 2026, primarily driven by $13.02 million in interest earned on trust account deposits. As a shell company, it continues to seek a business combination while maintaining a shareholders' deficit of $16.05 million due to the redemption value of Class A ordinary shares.
Bion Environmental Technologies reported a net loss of $768,992 for the quarter ended September 30, 2026, compared to a loss of $581,329 in the prior year period. The company generated no revenue during these periods as it shifted its focus toward smaller 'bolt-on' projects to accelerate technology validation and entry into the fertilizer markets by the 2026 growing season.
FF EAI Robotics Ecosystem Inc. reported its Q3 2026 financial results, highlighting $2.3 million in cumulative revenue and $593,000 in gross profit for its newly acquired robotics business. The company has transitioned into a pure-play humanoid and bionic Physical AI robotics ecosystem and plans to launch a 100-city robotics education initiative.
High Roller Technologies reported Q3 2026 financial results and highlighted the commercial launch of its ROLR prediction markets platform on October 21. The company ended the quarter with $13.4 million in cash and no debt, noting that revenue per depositing casino customer more than doubled year-over-year despite lower overall casino revenue due to market exits.
Term
Q3 2026
“On October 21, our ROLR prediction markets platform went live to the public, and High Roller formally entered its next chapter. The ROLR iOS app launched in the Apple App Store on November 9, and we plan to release our Android app in Q4 2026. We believe prediction markets have the potential to become the major growth driver for High Roller in 2027.”
Seth Young, Chief Executive Officer of High Roller Technologies
“Our Q3 2026 results reflect lower online casino revenue due to the year-over-year impact of having exited certain markets in 2025, as well as our continued investment to bring ROLR to market. The casino customers we serve today are more valuable, with revenue per depositing customer more than doubling year over year. We ended the quarter with $13.4 million in cash and cash equivalents and no outstanding borrowings, which we believe is sufficient to fund our operations for at least the next twelve months.”
Adam Felman, Chief Financial Officer of High Roller Technologies
Broadway Financial Corporation reported Q3 2026 net income attributable to common stockholders of $392 thousand, or $0.04 per diluted share, showing improvement over the prior quarter. The results were driven by strong loan growth of 11.4% and deposit growth of 21.0% during the first nine months of the year. CEO Brian Argrett highlighted the disciplined execution of strategic priorities and stable credit quality despite an evolving economic environment.
Term
Q3 2026
“Our third-quarter results reflect disciplined execution of our strategic priorities, resulting in strong growth in both loans and deposits while maintaining solid capital levels. We continue to operate with a disciplined approach to risk management and underwriting as we navigate an evolving economic environment.”
Transportation and Logistics Systems, Inc. reported a total shareholders' deficit of $21,999,597 as of September 30, 2026, with its primary operations classified as discontinued. The company faces significant liquidity challenges, including $7.2 million in liabilities from discontinued operations and a need for substantial additional financing to fund ongoing losses.
TaoWeave, Inc. reported its Q3 2026 results, highlighting significant activity in its Digital Assets segment, including unrealized gains from revaluations and realized gains from asset sales. The company also managed complex equity transactions involving Series F Preferred Stock and various warrant exercises, while maintaining distinct reporting for its Managed Services and Collaboration Products segments.
TherapeuticsMD reported net income of $0.49 million for the quarter ended September 30, 2026, compared to $0.15 million in the prior year period, driven by increased license revenue from its royalty-based business model. The company maintained a stable balance sheet with $10.4 million in cash and total stockholders' equity of $27.6 million.
IEH Corporation reported record financial results for its second fiscal quarter ended September 30, 2026, with revenue increasing 51% year-over-year to $10.7 million. The company achieved a record backlog exceeding $56 million and returned to profitability with net income of $1.36 million compared to a net loss in the prior year period.
Term
Q2 2027
“As great as this year’s first quarter was, the second quarter exceeded it by every measure. The first quarter’s record revenue of $10 million was eclipsed by this quarter’s $10.7 million. Similarly, our operating profit increased 57%, and our net income and earnings per share both more than doubled.”
Dave Offerman, President and CEO of IEH Corporation
“We shattered our previous backlog record by 40%, and we continue to hire and add capacity and equipment to meet the surge in demand in the defense, commercial aerospace, space and medical markets we serve.”
Dave Offerman, President and CEO of IEH Corporation
Seneca Bancorp, Inc. reported a net income of $129,000 for the nine months ended September 30, 2026, compared to $137,000 in the prior year period. While net interest income increased significantly to $7.7 million, the results were impacted by higher noninterest expenses, including a $262,000 impairment of long-lived assets and increased compensation costs.
Boston Omaha Corporation reported total revenues of $22.2 million for the third quarter of 2026, a slight increase from $21.9 million in the prior year. The company recorded a net loss attributable to common stockholders of $0.2 million for the quarter, an improvement from a $2.6 million loss in Q3 2025, primarily driven by equity in income of unconsolidated affiliates and income from discontinued operations.
Prospect Floating Rate & Alternative Income Fund, Inc. reported total investment income of $2.05 million for the quarter ended September 30, 2026, a slight decrease from $2.19 million in the prior year period. Net assets increased to $38.01 million from $37.10 million at fiscal year-end, while the net asset value per share for Class A and Class I shares decreased slightly to $3.88.
Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.
Lisata Therapeutics reported a significant increase in total assets to $648.4 million following the acquisition of Marea, which added $292.9 million in intangible assets and $64.7 million in goodwill. The company recorded a net loss of $6.8 million for the third quarter of 2026, with research and development expenses increasing to $5.2 million as they advance their combined pipeline.
For the three months ended September 30, 2026, OptimizeRx reported net revenue of $21.6 million and net income of $1.2 million, compared to $26.1 million and $0.8 million in the prior year period. While quarterly profitability improved, the company recorded a slight net loss of $3,000 for the nine-month period as revenues declined from $77.2 million to $62.0 million year-over-year.
Vistagen reported financial results for its fiscal year 2027 second quarter ended September 30, 2026, and provided a corporate update on its fasedienol Phase 3 development plan for social anxiety disorder. The company highlighted constructive FDA feedback regarding its clinical trial design and the appointment of Dr. Douglas J. Williamson to its Board of Directors. Vistagen also implemented cost-management initiatives to prioritize capital for its late-stage neuroscience programs.
Term
Q2 2027
“Following our recent productive meeting with the FDA and our evaluation of the extensive body of efficacy, safety, and patient experience data generated throughout Phase 2 and Phase 3 development of fasedienol, we believe we have clarity on the potential regulatory pathways forward for fasedienol in social anxiety disorder”
Shawn Singh, President and Chief Executive Officer of Vistagen
“Recent alignment of our operating structure and capital resources with our late-stage development opportunities in both social anxiety disorder and menopausal hot flashes, position us to execute our plan to advance these programs while maintaining flexibility to create long-term shareholder value.”
Shawn Singh, President and Chief Executive Officer of Vistagen